The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances in the context of a so-called open house procedure:

Deferasirox (V03AC03)

Distigmine (N07AA03)

Everolimus (L04AA18)

Fampridine (N07XX07)

Lanthanum (III) carbonate (V03AE03) only in the dosage form chewable tablets

Under standard contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances mentioned.

The earliest start of the contract is March 1, 2022. Based on this, the contract period is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances mentioned.

The earliest start of the contract is March 1, 2022. Based on this, the contract period is a maximum of 24 months.